124 related articles for article (PubMed ID: 9109538)
1. Is differential regulation of mitochondrial transcripts in Parkinson's disease related to apoptosis?
Ruberg M; Brugg B; Prigent A; Hirsch E; Brice A; Agid Y
J Neurochem; 1997 May; 68(5):2098-110. PubMed ID: 9109538
[TBL] [Abstract][Full Text] [Related]
2. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
4. trkB messenger RNA expression in normal human brain and in the substantia nigra of parkinsonian patients: an in situ hybridization study.
Benisty S; Boissiere F; Faucheux B; Agid Y; Hirsch EC
Neuroscience; 1998 Oct; 86(3):813-26. PubMed ID: 9692719
[TBL] [Abstract][Full Text] [Related]
5. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains.
Counihan TJ; Penney JB
J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
7. On the question of apoptosis in the parkinsonian substantia nigra.
Kösel S; Egensperger R; von Eitzen U; Mehraein P; Graeber MB
Acta Neuropathol; 1997 Feb; 93(2):105-8. PubMed ID: 9039456
[TBL] [Abstract][Full Text] [Related]
8. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
[TBL] [Abstract][Full Text] [Related]
9. Pathological changes in dendrites of substantia nigra neurons in Parkinson's disease: a Golgi study.
Patt S; Gertz HJ; Gerhard L; Cervós-Navarro J
Histol Histopathol; 1991 Jul; 6(3):373-80. PubMed ID: 1725760
[TBL] [Abstract][Full Text] [Related]
10. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
11. TNF-α regulates miRNA targeting mitochondrial complex-I and induces cell death in dopaminergic cells.
Prajapati P; Sripada L; Singh K; Bhatelia K; Singh R; Singh R
Biochim Biophys Acta; 2015 Mar; 1852(3):451-61. PubMed ID: 25481834
[TBL] [Abstract][Full Text] [Related]
12. Detrimental deletions: mitochondria, aging and Parkinson's disease.
Biskup S; Moore DJ
Bioessays; 2006 Oct; 28(10):963-7. PubMed ID: 16998822
[TBL] [Abstract][Full Text] [Related]
13. The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability.
Duke DC; Moran LB; Pearce RK; Graeber MB
Neurogenetics; 2007 Apr; 8(2):83-94. PubMed ID: 17211632
[TBL] [Abstract][Full Text] [Related]
14. Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.
Dutta D; Ali N; Banerjee E; Singh R; Naskar A; Paidi RK; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):804-821. PubMed ID: 28062948
[TBL] [Abstract][Full Text] [Related]
15. Regulation of c-Ret, GFRalpha1, and GFRalpha2 in the substantia nigra pars compacta in a rat model of Parkinson's disease.
Marco S; Saura J; Pérez-Navarro E; José Martí M; Tolosa E; Alberch J
J Neurobiol; 2002 Sep; 52(4):343-51. PubMed ID: 12210101
[TBL] [Abstract][Full Text] [Related]
16. The expression of mRNA for a kappa opioid receptor in the substantia nigra of Parkinson's disease brain.
Yamada M; Groshan K; Phung CT; Yamada M; Hisamitsu T; Richelson E
Brain Res Mol Brain Res; 1997 Feb; 44(1):12-20. PubMed ID: 9030693
[TBL] [Abstract][Full Text] [Related]
17. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic/xenogeneic transplantation of peptide-labeled mitochondria in Parkinson's disease: restoration of mitochondria functions and attenuation of 6-hydroxydopamine-induced neurotoxicity.
Chang JC; Wu SL; Liu KH; Chen YH; Chuang CS; Cheng FC; Su HL; Wei YH; Kuo SJ; Liu CS
Transl Res; 2016 Apr; 170():40-56.e3. PubMed ID: 26730494
[TBL] [Abstract][Full Text] [Related]
19. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine.
Thibaut F; Faucheux BA; Marquez J; Villares J; Menard JF; Agid Y; Hirsch EC
Brain Res; 1995 Sep; 692(1-2):233-43. PubMed ID: 8548309
[TBL] [Abstract][Full Text] [Related]
20. Cell death mechanisms in Parkinson's disease.
Jellinger KA
J Neural Transm (Vienna); 2000; 107(1):1-29. PubMed ID: 10809400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
